SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

__________ to _________

(Exact name of registrant as specified in its charter)

State or Other jurisdiction of

Incorporation or Organization

Route de la Corniche 4

Epalinges, Switzerland

011 41 21 653 4535

Registrant’s Telephone Number, Including Area Code

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer ☐		Accelerated filer ☐

	Non-accelerated filer ☐		Smaller reporting company ☒

	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

APPLICABLE ONLY TO CORPORATE ISSUERS

~~Indicate the~~The number of shares outstanding of ~~each of~~ the ~~registrant's classes of common stock,~~Registrant’s Common Stock, $0.01 par value, was 303,757,622 as of ~~the latest practicable date:~~May 15, 2020

~~Class~~		~~Outstanding at November 13, 2017~~
~~Common Stock, usd0.01 par value~~		~~303,757,622~~

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MYMETICS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands of Euros, Except Share and ~~Per Share Amounts)~~Par Value)

MYMETICS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In Thousands of Euros, Except Share and Per Share Data)

For The Three Months Ended
September 30,

For The Nine Months Ended
September 30,

2017

2016

2017

2016

Revenue

Research and development services
E--
E30
E202
E379
Grants
  399
  149
  897
  528

  399
  179
  1,099
  907
Expenses




Research and development
  555
  241
  1,522
  599
General and administrative
  276
  298
  900
  930
Bank fee
  1
  1
  2
  2
Depreciation
  10
  11
  28
  33
Directors' fees
  5
  5
  15
  15
Foreign exchange and other
  (78)
  (20)
  (285)
  (62)

  769
  536
  2,182
  1,517





Operating loss
  (370)
  (357)
  (1,083)
  (610)





Interest expense
  647
  642
  1,942
  1,926
Loss before income tax (provision) benefit
  (1,017)
  (999)
  (3,025)
  (2,536)





Income tax (provision) benefit
  (3)
  (4)
  (6)
  16
Net loss
  (1,020)
  (1,003)
  (3,031)
  (2,520)





Other comprehensive loss




Foreign currency translation adjustment
  (9)
  --
  (18)
  (4)
Comprehensive loss
E(1,029)
E(1,003)
E(3,049)
E(2,524)










Basic earnings per share
E(0.00)
E(0.00)
E(0.01)
E(0.01)
Diluted earnings per share
E(0.00)
E(0.00)
E(0.01)
E(0.01)

	Three Months Ended March 31,
	2020	2019
Revenue
Research and Development services	E17	E--
Grants revenue	255	--
	272	--
Expenses
Research and development	322	215
General and administrative	325	278
Other	106	66
	753	559
Operating Loss	(481)	(559)

Interest expense	675	666
Loss before income tax provision	(1,156)	(1,225)

Income tax provision	(8)	(3)
Net Loss	(1,164)	(1,228)

Other comprehensive loss
Foreign currency translation adjustment	7	5
Comprehensive loss	E(1,157)	E(1,223)

Basic and diluted earnings per share	E(0.00)	E(0.00)
Weighted-average shares outstanding, basic and diluted	303,757,622	303,757,622

MYMETICS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT

(In Thousands of Euros)

	Three-month Period Ended March 31, 2019
	Common Stock Number of Par
	Shares	Value	Additional Paid in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
January 1, 2019	303,757,622	E2,530	E34,441	E(84,675)	E679	E(47,025)
Stock compensation expense		-	2			2
Net loss	-	-	-	(1,228)	-	(1,228)
Other comprehensive loss:	-
Translation adjustment	-	-	-	-	5	5
March 31, 2019	303,757,622	E2,530	E34,443	E(85,903)	E684	E(48,246)��

	Three-month Period Ended March 31, 2020
	Common Stock Number of Par
	Shares	Value	Additional Paid in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
January 1, 2020	303,757,622	E2,530	E34,443	E(88,862)	E691	E(51,198)
Stock compensation expense			-			-
Net loss	-			(1,164)		(1,164)
Other comprehensive loss:	-
Translation adjustment	-				7	7
March 31, 2020	303,757,622	E2,530	E34,443	E(90,026)	E698	E(52,355)

MYMETICS CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands of Euros)

For The Nine Months Ended

September 30,

For The Three Months Ended

March 31,

MYMETICS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER 30, 2017~~MARCH 31, 2020

Note 1. The Company and Summary of Significant Accounting Policies

BASIS OF PRESENTATION AND GOING CONCERN

The amounts in the notes are shown in thousands of EURO, unless otherwise noted, and rounded to the nearest thousand except for share and per share amounts.

The accompanying interim period condensed consolidated financial statements of Mymetics Corporation (the "Company") set forth herein have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period condensed consolidated financial statements should be read together with the audited financial statements and the accompanying notes included in the Company's latest annual report on Form 10-K for the fiscal year ended December 31, ~~2016.~~2019.

The accompanying financial statements of the Company are unaudited. However, in the opinion of the Company, the unaudited condensed consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. All adjustments made during the ~~nine-month~~three-month period ending ~~September 30, 2017~~March 31, 2020 were of a normal and recurring nature.

The Company was created for the purpose of engaging in vaccine research and development. Its main research efforts in the beginning have been concentrated in the prevention and treatment of the AIDS virus and malaria. The Company has established a network which enables it to work with education centers, research centers, pharmaceutical laboratories and biotechnology companies. Besides the HIV and malaria vaccine candidates under development, the Company additionally has the following vaccines in its ~~pipeline.~~pipeline; (i) Herpes Simplex which is at the ~~preclinical~~pre-clinical stage and currently on hold, (ii) ~~an intra nasal~~ influenza ~~vaccine~~for elderly which has finished a clinical trial Phase I, (iii) Respiratory Syncytial Virus ~~(RSV)~~(“RSV”) which is at the ~~preclinical~~pre-clinical stage and currently on hold and (iv) Chikungunya virus at the discovery ~~stage.~~stage and currently on hold.

As of ~~September 30, 2017,~~March 31, 2020, the Company iswas engaged in the ~~preclinical~~pre-clinical testing of some of its vaccine candidates ~~and~~but a commercially viable product is not expected for several more years. However, the Company generated some revenue as of the prior quarter through ~~a small research project with Sanofi for influenza vaccines and from~~ collaboration and grant ~~agreements~~agreements. The Company is working on several research projects with commercial partners for ~~R&D services. Management believes that the Company’s research and development activities will result in valuable intellectual property that can generate significant revenues~~immunotherapy in the ~~future such as by licensing. Vaccines are one~~fields of allergy and oncology and for some infectious diseases with academic partners. The allergy project is in collaboration with Anergis SA, for which the Company prepared virosome-based vaccines which include Anergis peptides for treating birch pollen allergy. These formulations were tested in preclinical studies and compared to the Anergis earlier formulations. The success criteria were met and Anergis has now a time limited exclusive option to enter into a License and Collaboration Agreement with Mymetics for the use of virosomes in the field of allergies. During the last quarter of 2019, the Company signed Amendment 3 of the ~~fastest growing markets~~Research and Option to License Agreement and in October, 2019, Mymetics announced that Stallergenes Greer, a worldwide leader in Allergen Immunotherapy (“AIT”), and Anergis, started a new research study to evaluate the ~~pharmaceutical industry.~~effects of the second generation virosome-based COP allergen immunotherapy in a therapeutic model of birch allergy in mice.

These condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced negative cash flows from operations and significant losses since inception resulting in an accumulated deficit of ~~E79,422~~E90,026 at ~~September 30, 2017.~~March 31, 2020. Further, the Company’s current liabilities exceed its current assets by ~~E48,541~~E59,180 as of ~~September 30, 2017,~~March 31, 2020, and there is no assurance that cash will become available to pay current liabilities in the near term. Management is seeking additional financing but there can be no assurance that management will be successful in any of those efforts. These conditions raise substantial doubt about ~~the Company’s~~our ability to continue as a going ~~concern.~~concern within one year from the issuance of the financial statements.

CORRECTTION OF PRIOR PERIOD IMMATERIAL ERROR

During the three months ended March 31, 2020, management discovered that the Company had not increased the right of use asset and corresponding operating lease liability in October 2019 at the time the Leiden, The Netherlands, lease was extended.

The Company evaluated the impact of the error on prior periods and determined that the effect was not material to the financial statements as of December 31, 2019. The Company corrected the error in the unaudited condensed consolidated financial statements as of March 31, 2020. The correction of the error increased the Company's right of use asset and lease liability by E203.

The Company’s consolidated statements of operations, comprehensive loss and cash flows for the year ended December 31, 2019, were not affected by this correction of the error. Accordingly, the Company's loss per share for the year ended December 31, 2019 remains unchanged. As a result, the condensed consolidated balance sheet has been revised to reflect this change to the applicable line items as follows:

	December 31, 2019
	As Originally Reported	Adjustment	As Revised

Right-of-Use asset	E27	E203	E230

Operating lease liability (short-term)	E-	E102	E102
Operating lease liability (long-term)	E27	E101	E128

Total assets	E 7,682	E 203	E 7,885
Total current liabilities	E 58,583	E 102	E 58,955
Total liabilities	E 58,880	E 203	E 59,083

IMPACT OF THE NOVEL CORONAVIRUS

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.

The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on the Company’s financial condition, liquidity, and future results of operations.

Management is actively monitoring the global situation on its financial condition, liquidity, operations, scientific collaborations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year 2020.

The Company’s partner for the oncology immunotherapy project in the Netherlands has decreased their laboratory experiments due to reduced operating hours in those facilities. While the Company considers this disruption to be temporary, continued disruption in this project will lead to delayed advances by the Company of its research and could negatively impact future revenue in fiscal year 2020 and the Company’s overall liquidity.

The Company is dependent on its workforce to deliver and advance its research. Developments such as physical distancing and working from home directives will impact the Company’s ability to deploy its workforce effectively. While expected to be temporary, prolonged workforce disruptions may negatively impact future revenues in fiscal year 2020 and the Company’s overall liquidity.

The Company is dependent on its partners in certain projects, such as the University of Louisiana at Lafayette (“ULL”) for the NIH funded project to maintain the agreed timelines and execute their tasks. Developments such as social distancing and shelter-in-place directives and lock-down directives will impact the Company’s ability to execute on project plans and research objectives effectively. While expected to be temporary, prolonged disruptions in collaboration projects may negatively impact funding in fiscal year 2020 and the Company’s overall liquidity.

Although the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may have a material adverse effect on the Company’s results of future operations, financial position, and liquidity in fiscal year 2020.

CORONAVIRUS AID, RELIEF AND ECONOMIC SECURITY ACT

On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law. The CARES Act includes various income and payroll tax provisions. The Company has analyzed the tax provisions of the CARES Act and determined they have no significant financial impact to the condensed financial statements. The Company has no intention of taking advantage of other benefits provided by the CARES Act but will continue to evaluate the impact on the Company’s financial position.

PRINCIPLES OF CONSOLIDATION

NEW ACCOUNTING PRONOUNCEMENT

On January 1, 2020, the Company adopted Accounting Standard Update ("ASU") No. 2018-13,Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement,to improve the effectiveness of disclosures. The amendments remove, modify, and add certain disclosure requirements in Topic 820, “Fair Value Measurement.” The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The adoption had no impact on the Company's condensed consolidated financial statements.

FOREIGN CURRENCY TRANSLATION

The Company translates non-Euro assets and liabilities of its subsidiaries at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the average rate of exchange throughout the period. Unrealized gains or losses from these translations are reported as a separate component of comprehensive ~~loss.~~income. Transaction gains or losses are included in ~~operating~~general and administrative expenses in the consolidated statements of comprehensive loss. The translation adjustments do not recognize the effect of income tax because the Company expects to reinvest the amounts indefinitely in operations. The Company's reporting currency is the Euro because substantially all of the Company's activities are conducted in Europe.

~~Exclusive Licenses~~Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The ~~deliverables under an exclusive license agreement generally include~~Company has concluded that government grants are not within the ~~exclusive license~~scope of Topic 606, as they do not meet the definition of a contract with a “customer”. We concluded the definition of a contract with a “customer” was not met as the counterparty to the ~~Company’s technology,~~government grants has not contracted to obtain goods or services and ~~may also include deliverables~~thus the contracts are not considered to have commercial substance. Government grants provide the Company with payments for certain types of expenditures related to research and development activities over a contractually defined period. Revenue from government grants is recognized in the period during which the related costs are incurred, provided that the applicable conditions under the government contracts have been met.

On April 29, 2019, the National Institutes of Health (“NIH”) awarded the Company and Texas Biomedical Research Institute (“Texas Biomed”) a five-year grant for the project called “Cold Chain-independent, Needle-free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels”. The project started on May 1, 2019 and is planned for five years. The overall budget related to the project is USD 8,850, with USD 1,940 approved for the first year. The overall portion of the grant allocated to the Company is USD 5,930, with USD 1,190 approved for the first year. It was initially co-led by Texas Biomed, but due to the move of Dr. Ruth Ruprecht, the Co-Principal Investigator, to the University of Louisiana at Lafayette (“ULL”) at the end of 2019, ULL has become the co-lead with Mymetics for this project. To date, the Company has recognized E797 of grant revenue from the NIH, of which E255 has been recognized during the quarter ended March 31, 2020. First results are expected to be ~~performed on behalf~~reported in 2020.

The project has the objective to prepare the Company’s promising HIV-1 vaccine candidate for clinical trials, by first executing a non-human primate (“NHP”) study, where the test subjects will be receiving Mymetics’ virosome based HIV-1 vaccine candidate by several intra-muscular and intra-nasal applications, followed by rectal challenges. As of March 31, 2020, Mymetics has successfully produced two sets of virosome based vaccines and the NHPs have received two intramuscular vaccinations and three intranasal vaccinations. The vaccinations were well tolerated and there were no safety issues. The intra-rectal challenge study has now started. The vaccine is created to induce protective mucosal antibodies acting as a frontline defense against sexual HIV transmission. This newly awarded grant from the NIH can continue some of the ~~collaborative collaborator~~developments that were achieved during the European Horizon 2020 project.

License Agreement – UPPERTON Ltd.

On July 26, 2019 Mymetics and Upperton Ltd. signed a License Agreement (the “Agreement”) that sets out the rights and obligations of the two parties with respect to the development, manufacturing and exploitation of certain virus-like particles based vaccines (which includes virosomes) into solid (powder or tablet) form that are based on each party’s background or pre-existing intellectual property (“IP”) and the ~~manufacture of preclinical~~foreground IP rights or ~~clinical materials for~~ the ~~collaborative collaborator.~~IP that was developed by either party or both parties during the Maciviva project and could be developed during future collaborations.

~~Generally, exclusive license and or collaboration agreements contain nonrefundable terms for payments and, depending on~~Under the terms of the ~~agreement, provide that~~Agreement Mymetics receives an exclusive and royalty-free, worldwide license to use the ~~Company will (i) provide research services which are reimbursed at a contractually determined rate which includes margin~~Upperton background IP for the ~~Company, (ii) participate~~development, research, sale or in/out license for virus-like particle vaccines that use the foreground IP rights. All title, right and interest in and to all foreground IP rights vests in Mymetics for such development, research, sale or in/out license, and Mymetics is free to use and exploit such foreground IP rights. Mymetics has provided Upperton the non-exclusive license to manufacture virus-like particle-based vaccines for third parties for indications other than respiratory viruses, certain allergies, HIV, malaria and chikungunya. For these foreground IP licenses, the parties have agreed to pay each other a ~~joint steering committee to monitor the progress~~certain low single digit percentage of ~~the research~~revenues, license fees and development which will be reimbursed at a contractually determined rate which includes margin for the Company, (iii) earn payments upon the achievement of certain milestones and (iv) earn royalty payments at the time of commercialization until the later of expiration of the last to expire valid patent rights expire or 10 years after the first commercial sale. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements. The Company does not directly control when any collaborator will request research or manufacturing services, achieve milestones or become liable for royalty payments. As a result, the Company cannot predict when it will recognize revenues in connection with any of the foregoing.

The Company follows the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, "Revenue Recognition—Multiple Element Arrangements," and ASC Topic 605-28, "Revenue Recognition—Milestone Method," in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has standalone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied toroyalties that each of the ~~separate units. Factors considered in this determination include~~parties receives from their exploitation. No revenue has been received nor recognized during the ~~research and manufacturing capabilities~~quarter ended March 31, 2020.

License Agreement – ANERGIS SA

In December 2018, the Company announced that the success criteria of the ~~collaborator~~Research and Option to License Agreement with Anergis SA (“Anergis”) had been met. Under the ~~availability~~terms of ~~technology research expertise in~~ the ~~general marketplace.~~Research Agreement, a pre-clinical study program evaluated the immunogenicity profile of the Anergis’ peptides designed to treat birch allergy when presented on Mymetics’ proprietary virosomes, with or without undisclosed TLR ligands or other adjuvants, and these results were compared to Anergis’ AllerT product combination.

~~Fixed price contracts~~Should Anergis and ~~research~~Mymetics execute a License and ~~collaboration agreements~~Collaboration Agreement (“LCA”), Anergis would make an upfront payment to Mymetics in an amount that increases as the date of the LCA is executed. The LCA also includes milestone payments based on certain regulatory clearances and royalties for net sales. The contractual material had been delivered during the third quarter of the year 2018 and 100% of the agreed payments from the Research and Option to License Agreement has been received and fully recognized as revenue in Q3 2018. The LCA has not been executed as of the date this report has been filed. During the last quarter of 2019, the Company received an amount of E111 related to the Amendment 3 of the Research and Option to License Agreement dated September 3rd, 2019. This revenue has been fully recognized as the deliverables for the Stallergenes-Anergis study were met and Anergis paid for an extension of the option to execute the LCA.

When the performance under a fixed price contract can be reasonably estimated, revenue for such a contract is recognized under the proportional performance method and earned in proportion to the contract costs incurred in performanceAs of the work as compared to total estimated contract costs. Costs incurred under fixed price contracts represent a reasonable measurement of proportional performance of the work. Direct costs incurred under collaborative research and development agreements are recorded as research and development expenses. If the performance under a fixed price contract cannot be reasonably estimated, the Company recognizes the revenue on a straight-line basis over the contract term.

~~In April 2015,~~December 31, 2019, the Company was ~~selected to receive project grants~~engaged in the pre-clinical testing of some of its vaccine candidates and a commercially viable product is not expected for several more years. The success criteria were met in December 2018. In October 2019 Anergis started a new evaluation study in collaboration with ~~a total of E8.4 million. A total of E5.3 million is funded as part of Horizon 2020,~~Stallergenes Greer SA, in which the ~~European Union research and innovation framework program and up to E3.1 million of funding~~Mymetics COP virosomes will be ~~provided by~~evaluated in a preclinical study. Anergis has a time limited option to license the ~~Swiss State “Secretariat for Education, Research~~virosomes from Mymetics in the field of allergies that will require Anergis to raise funds from third parties to pay Mymetics the license fee under the terms of the License and ~~Innovation” (SERI) for~~Collaboration Agreement and the ~~Swiss based consortium partners. The grant funds the evaluation,~~clinical development, and ~~manufacturing scale-up of thermo-stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. Of the total amount, E3.4 million~~there is directly attributable to Mymetics’ activities, with the remaining balance going to the consortium partners. The project duration is 42 months and started on May 4, 2015. The Company received a pre-payment from the two granting organizations for a total value of E1.5 million in May 2015, a second tranche of E917 from the EU was received in December 2016, and E614 from “SERI” was received in April 2017, whichno certainty that Anergis will be ~~used~~able to finance the next reporting covering the period of November 2016 to October 2017. Thereafter another tranche of funding from the EU will be received which, accumulated with earlier tranches, cannot exceed 90% of the agreed budget. The pre-payments have been recorded as a current liability in deferred revenue anddo so. No revenue has been received nor recognized ~~as services are delivered.~~during the quarter ended March 31, 2020.

~~SANOFI PASTEUR BIOLOGICS~~

On December 1, 2016, Mymetics Corporation entered into a material definitive Research Agreement with Sanofi Pasteur Biologics, LLC, the vaccine division of Sanofi (SNY). The project will investigate the immunogenicity of influenza vaccines based on the Company’s proprietary virosome technology platform in preclinical settings. If this project is successful it could result in a further and more extensive collaboration between the two companies. The project duration is six to twelve months and started in January 2017. The revenue is recognized upon delivery of the contractual material.

Receivables are stated at their outstanding principal balances. Management reviews the collectability of receivables on a periodic basis and determines the appropriate amount of any allowance. There was no allowance necessary at ~~September 30, 2017~~March 31, 2020 or December 31, ~~2016.~~2019. The Company ~~charges~~writes off receivables to the allowance when management determines that a receivable is not collectible. The Company may retain a security interest in the products sold.

PROPERTY AND EQUIPMENT

Property and equipment is recorded at cost and is depreciated over its estimated useful life on straight-line basis from the date placed in service. Estimated useful lives are usually taken as three years.

IMPAIRMENT OF ~~LONG LIVED~~LONG-LIVED ASSETS

Long-lived assets, which include property and equipment, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying value of the assets exceeds the undiscounted future cash flows generated by that asset and the carrying value is not considered recoverable, impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. An impairment loss would be recognized in net income (loss) in the period that the impairment occurs.

Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of a business acquired. The Company typically performs its annual goodwill impairment test effective as of April 1 of each year, unless events or circumstances indicate impairment may have occurred before that time. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. After assessing qualitative factors, the Company determined that no further testing was necessary. If further testing was necessary, the Company would determine the fair value of each reporting unit, and compare the fair value to the reporting ~~unit's~~unit’s carrying amount. ~~An impairment loss would be recognized for the excess of a~~The Company has one reporting ~~unit's carrying amount over its fair value. As of September 30, 2017, management believes there are no indications of impairment.~~unit.

RESEARCH AND DEVELOPMENT

The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates.

The Company reports a liability, if any, for unrecognized tax benefits resulting from uncertain income tax positions taken or expected to be taken in an income tax return. Estimated interest and penalties, if any, are recorded as a component of interest expense and other expense, respectively.

The Company has not recorded any liabilities for uncertain tax positions or any related interest and penalties at ~~September 30, 2017~~March 31, 2020 or December 31, ~~2016.~~2019. The Company’s United States tax returns are open to audit for the years ended December 31, ~~2014~~2015 to ~~2016.~~2018. The returns for the Swiss subsidiary, Mymetics S.A., are open to audit for the ~~years~~year ended December 31, ~~2010 to 2016.~~2019. The returns for the Netherlands subsidiaries, Bestewil B.V. and Mymetics B.V., are open to audit for the year ended December 31, ~~2016.~~2019.

Basic earnings per share is computed by dividing net income or loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. Diluted earnings per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. For the ~~periods~~quarters ended ~~September 30, 2017~~March 31, 2020 and ~~2016,~~2019, options and convertible debt were not included in the computation of diluted earnings per share because their effect would be anti-dilutive due to net losses incurred under the treasury stock method.

For the three and nine months ended September 30, 2017, the basic weighted and diluted average number of shares was 303,757,622. The total potential number of shares issuable of 614,033,846 at September 30, 2017 includes 584,933,846 potential issuable shares related to convertible loans, and 29,100,000 potential issuable shares related to outstanding stock options granted to employees.

For the three months ended ~~September 30, 2016,~~March 31, 2020, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of ~~577,568,516~~703,131,197 at ~~September 30, 2016~~March 31, 2020 includes ~~548,334,168~~676,381,197 potential issuable shares related to convertible loans and ~~29,234,348~~26,750,000 potential issuable shares related to outstanding ~~stock~~not expired options granted to employees.

For the ~~nine~~three months ended ~~September 30, 2016,~~March 31, 2019, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of ~~577,580,317~~668,933,362 at ~~September 30, 2016~~March 31, 2019 includes ~~548,334,168~~639,833,362 potential issuable shares related to convertible loans and ~~29,246,149~~29,100,000 potential issuable shares related to outstanding ~~stock~~not expired options granted to employees.

The Company has authorized 5,000,000 shares of preferred stock that may be issued in several series with varying dividend, conversion and voting rights. No preferred shares are issued or outstanding at ~~September 30, 2017~~March 31, 2020 or December 31, ~~2016.~~2019.

STOCK-BASED COMPENSATION

Compensation cost for all share-based payments is based on the estimated grant-date fair value. The Company amortizes stock compensation cost ratably over the requisite service period.

The issuance of common shares for services is recorded at the quoted price of the shares on the date the shares are issued. No shares were issued to individuals as fee for services rendered in the ~~nine~~three months ended ~~September 30, 2017~~March 31, 2020 nor in the ~~nine~~three months ended ~~September 30, 2016.~~March 31, 2019.

~~During the three month periods ended September 30, 2017 and 2016, stock compensation expense amounted to E13 and E18, respectively.~~ Stock compensation expense amounted to ~~E31~~E0 and ~~E63~~E2 during the ~~nine month~~three months periods ended ~~September 30, 2017~~March 31, 2020 and ~~2016,~~2019, respectively, and is included in the condensed consolidated statements of comprehensive loss within general and administrative expenses.

The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

FAIR VALUE MEASUREMENTS

Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

Level 1-
1 -

Quoted prices in active markets for identical assets or liabilities.

Level 2-
2 -

Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3-
3 -

Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

FAIR VALUES OF FINANCIAL INSTRUMENTS

The Company generally has the following financial instruments: cash, receivables, accounts payable, and notes payable. The carrying value of cash, receivables and accounts payable, approximates their fair value based on the short-term nature of these financial instruments. Management believes ~~that it is not practicable to estimate~~ the fair value of the notes payable ~~due to conversion features and~~is reflecting the ~~unique nature of~~actual value reported for these instruments.

The Company derived ~~100% and 83%~~94% of grant revenue for the three-month period ended March 31, 2020 from ~~its relationship with~~ one collaborative partner during the three month periods ended September 30, 2017 and September 30, 2016, respectively, and 82% and 57% with the same collaborative partner during the nine month periods ended September 30, 2017 and September 30, 2016, respectively.partner.

RELATED PARTY TRANSACTIONS

Mr. Ernest M. Stern, the Company’s outside U.S. counsel, is both a director of the Company and ~~was~~is a partner in ~~Akerman LLP,~~Culhane Meadows PLLC, the firm retained as legal counsel by the Company. Mr. Stern resigned from the firm Akerman LLP and became a partner in the law firm of Culhane Meadows PLLC as of March 1, 2017. Culhane Meadows PLLC is the Company’s legal counsel effective March 1, 2017. The Company incurred professional fees to the counsel's law ~~firms~~firm totaling ~~E31~~E11 and ~~E51~~E8 for the ~~nine~~three months ended ~~September~~ ~~30, 2017~~March 31, 2020 and ~~2016,~~2019, respectively.

Two of the Company’s major shareholders have granted secured convertible notes and ~~short term~~short-term convertible notes and promissory notes, which have a total carrying amount of ~~E48,276,~~E59,004, including interest due to date. Conversion prices on the Euro-denominated convertible debt have been fixed to a fixed Euro/US dollar exchange rate.

~~NEW ACCOUNTING PRONOUNCEMENTS~~

On May 28, 2014, FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, Topic 606, requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. The updated standard becomes effective for us in the first quarter of fiscal 2018. The Company is in the process of analyzing the impact adoption will have on our annual and interim financial statements. The Company will also be required to make additional disclosures under the new guidance. We continue to assess the impact on all areas of our revenue recognition, disclosure requirements, and changes that may be necessary to our internal controls over financial reporting.

In January 2017, the FASB issued ASU 2017-04, Intangibles, Goodwill and Other, to supersede the current guidance by replacing the current two-step impairment test with a one-step impairment test. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for goodwill impairment tests performed after January 1, 2017. The Company elected early adoption as of January 1, 2017. Adoption of this standard did not have an impact on Company's consolidated financial statements.

Note 2. Debt Financing

Certain principal shareholders have granted the Company secured convertible notes (in accordance with the Uniform Commercial Code in the State of Delaware), short term convertible notes and other ~~short term~~short-term notes, which have a total carrying value of ~~E48,276~~E59,417 including interest due to date. Interest incurred on these notes since inception has been added to the principal amounts.

(1)

Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated ~~in U.S. dollars~~ at ~~$190.~~USD 190.

(2)

This maturity date is automatically prolonged for periods of three months, unless called for repayment.

(3)

Renamed Hyposwiss Private Bank Genève S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

(4)

The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV and against all property of the Company.

(5)

The face values of the loans are stated ~~in U.S. dollars~~ at ~~$1,200~~USD 1,200 and ~~$300,~~USD 300, respectively.

(6)

This maturity date is automatically prolonged for periods of three months, unless called for repayment. The conversion price per share is determined by the lower of (i) reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with an investment in the Company of not less than ~~US$~~USD 20,000, or (ii) at the stated conversion price using a fixed exchange rate which are noted in the table above.

(7)

On ~~March~~June 1, ~~2017,~~2018, Round Enterprises Ltd. and Eardley Holding AG each provided two promissory Notes for a total of ~~E1,840~~E1,280 and ~~E460,~~E320 in two tranches, respectively, with a 2.5% interest per ~~annum and a maturity date of February 28, 2018.~~annum. The first ~~50%~~tranche of the promissory Notesof ~~E920~~E640 and ~~E230,~~E160, respectively, were provided immediately.The second ~~50%~~tranche of the promissory notes of ~~E920~~E640 and ~~E230,~~E160, respectively, were provided on ~~October 18, 2017.~~November 10, 2018 with a 2.5% interest per annum. The maturity date of these promissory notes to follow the same principle of other convertible loans and is the later of (i) June 30, 2019, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

(8)

On June 15, 2019, Round Enterprises Ltd. and Eardley Holding AG each provided a promissory Note of E480 and E120, respectively, with a 2.5% interest per annum. The maturity date of these promissory notes to follow the same principle of other convertible loans and is the later of (i) December 31, 2019, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

(9)

On December 20, 2019, Round Enterprises Ltd. and Eardley Holding AG each provided a promissory Note of E480 and E120, respectively, with a 2.5% interest per annum. The maturity date of these promissory notes to follow the same principle of other convertible loans and is the later of (i) June 30, 2020, or (ii) the end of a subsequent calendar quarter in which the Company receives a written request from the lender for repayment of the unpaid principal and accrued interest due under the Notes.

Note 3. Commitments

The facility lease agreement for Epalinges, Switzerland, is automatically renewed month by month with a notice period of three months. The related rent is paid monthly in the amount of E4 and is considered a short-term lease. The facility lease agreement for Leiden, The Netherlands, runs until March 31, 2020 but was renewed until March 31, 2022 and can be terminated with a six month notice as of September 30, 2021. The related rent is paid monthly in the amount of E9. The Company does not have any other operating lease for its research and development facilities, corporate headquarter, offices and equipment.

Note 3.4. Subsequent Events

On ~~October 18, 2017, Eardley Holding AG~~April 2, 2020, the Swiss entity, Mymetics SA, received a Federal credit line of Chf 168 (E159) in relation with the Covid-19. This credit line applies for five years and ~~Round Enterprises Ltd. executed~~is fully guaranteed by the second set of promissory notes for a total of E1,150. These notes have the same terms and conditions as the first set of promissory notes issued on March 1, 2017, with an interest of 2.5% per annum and a maturity date of October 18, 2018.

On October 20, 2017, the Company entered into an Amendment of the Research Agreement dated December 1, 2016 with Sanofi Pasteur Biologics, LLC, the vaccine division of Sanofi SA, (“Sanofi”), to extend the date of the Research Agreement for an additional year. Under the terms of the Research Agreement Sanofi wanted to compare the immunogenicity of Mymetics’ influenza virosomes compared to Sanofi Pasteur’s egg-based split vaccine.Swiss Confederation via guarantee organizations. The interest rate is currently at 0 percent but can be adjusted as of Sanofi in a collaboration with Mymetics was based on the results of preclinical and clinical studies a few years ago with Solvay Pharmaceuticals that was acquired by Abbott in 2013. The initial results of the recent study did not achieve the expected benefits of Mymetics’ influenza virosomes and were contrary to earlier results Mymetics obtained with Solvay in multiple studies. Mymetics believes that there was an issue with the influenza virosome formulations that were produced. Mymetics has agreed to pay for a redesigned study, which Mymetics believes will be approximately US$125,000.-. Following the new study in the coming months, Mymetics will review the outcomes with Sanofi and determine next steps.April 1, 2021.

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

GENERAL

The following discussion and analysis of the results of operations and financial condition of Mymetics Corporation for the periods ended ~~September 30, 2017~~March 31, 2020 and ~~2016~~2019 should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, ~~2016~~2019 and related notes and the description of the Company's business and properties included elsewhere herein.

This report contains forward-looking statements that involve risks and uncertainties. The statements contained in this report are not purely historical but are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward looking statements concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Words such as "may," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue", "probably" or similar words are intended to identify forward looking statements, although not all forward looking statements contain these words.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We are under no duty to update any of the forward-looking statements after the date hereof to conform such statements to actual results or to changes in our expectations.

Readers are urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation disclosures made under the captions "Management Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors," "Consolidated Financial Statements" and "Notes to Consolidated Financial Statements" included in our annual report on Form 10-K for the year ended December 31, ~~2016~~2019 and, to the extent included therein, our quarterly reports on Form 10-Q filed during fiscal year ~~2017.~~2019.

IMPACT OF THE NOVEL CORONAVIRUS

CORONAVIRUS AID, RELIEF AND ECONOMIC SECURITY ACT

On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law. The CARES Act includes various income and payroll tax provisions. The Company has analyzed the tax provisions of the CARES Act and determined they have no significant financial impact to the condensed financial statements. The Company has no intention of taking advantage of other benefits but will continue to evaluate the impact on the Company’s financial position.

THREE MONTHS ENDED ~~SEPTEMBER 30, 2017~~MARCH 31, 2020 AND ~~2016~~2019

~~Revenue was E399 and E179 for~~For the three months ended ~~September 30, 2017 and 2016, respectively, mainly~~March 31, 2020, revenue was E272, of which E255 was related to the revenue recognized for the work performed under the ~~Horizon 2020 grants.~~NIH grant / HIV project and the remaining for a small pre-clinical research project with a US academic institution. No revenue was earned for the three months ended March 31, 2019.

Costs and expenses increased to ~~E769~~E753 for the three months ended ~~September 30, 2017~~March 31, 2020 from ~~E536 (43.5%~~E559 (+34.7%) for the three months ended ~~September 30, 2016,~~March 31, 2019. The increase is mainly due to the ~~subcontracting services~~R&D costs related to the ~~Horizon 2020~~work performed under theNIH grant / HIV project ~~with acronym “Maciviva” (Manufacturing process for Cold-chain Independent Virosome-based Vaccines)~~ ~~incurred during~~and foreign exchange loss from the ~~three months ended September 30, 2017.~~revaluation of shareholders’ loans based in USD.

Research and development expenses increased to ~~E555~~E322 in the current period from ~~E241 (130.3%~~E215 (+49.8%) in the comparative period of ~~2016,~~2019, mainly due to ~~the~~E88 of subcontracting services ~~related to the project with acronym “Maciviva”~~paid during the ~~three month~~three-month period ending ~~September 30, 2017.~~March 2020 in relation with the NIH grant / HIV project.

General and administrative expenses ~~decreased~~increased to ~~E276~~E325 in the ~~three months ended September 30, 2017~~current period from ~~E298 (-7.4%~~E278 (+16.9%) in the comparative period of ~~2016.~~2019, mainly due to the D&O liability annual insurance premium expensed during the three months ended March 2020, and increase of the annual audit fees.

Other expenses increased to E95 for the three months ended March 31, 2020 from E55 (+72.7%) for the three months ended March 31, 2019, mainly due to the foreign exchange revaluation impact of shareholders’ loans based in US$.

Interest expense increased to E675 for the three months ended March 31, 2020 from E666 for the three months ended March 31, 2019 related to existing loans from third party investors.

The Company reported a net loss of ~~(E1,020)~~(E1,164), or (E0.00) per share, for the three months ended ~~September 30, 2017,~~March 31, 2020, compared to a net loss of ~~(E1,003)~~(E1,228), or (E0.00) per share, for the three months ended ~~September 30, 2016.~~

~~NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016~~

Revenue was E1,099 and E907 for the nine months ended September 30, 2017 and 2016, respectively. The increase was mainly related to the revenue recognition of the GMP production related to the Maciviva project.

Costs and expenses increased to E2,182 for the nine months ended September 30, 2017 from E1,517 (43.8%) for the nine months ended September 30, 2016, mainly due to the reversal of aged R&D cost accrual of E154 during the nine months ended September 30, 2016 and ~~to the subcontracting services related to the project with acronym “Maciviva” during the nine month period ending~~ ~~September~~ ~~30, 2017.~~

Research and development expenses increased to E1,522 in the current period from E599 (154.1%) in the comparative period of 2016, mainly due to the reversal of aged R&D cost accrual of E154 during the nine months ended September 2016, and subcontracting cost paid to vendor for Good Manufacturing Production launched during the nine months ended September 30, 2017.

~~General and administrative expenses decreased to E900 in the nine months ended September 30, 2017 from E930 (-3.2%) in the comparative period of 2016.~~

Foreign exchange revaluation generated a net gain of E285 during the nine months ended September 30, 2017 and a net gain of E62 during the nine months ended September 30, 2016, which is mainly due to the revaluation of existing US$ based loans from related parties.

The Company reported a net loss of (E3,031), or (E0.01) per share, for the nine months ended September 30, 2017, compared to a net loss of (E2,520), or (E0.01) per share, for the nine months ended September 30, 2016.March 31, 2019.

LIQUIDITY AND CAPITAL RESOURCES

We had cash of ~~E830~~E231 at ~~September 30, 2017~~March 31, 2020 compared to ~~E1,391~~E475 at ~~December~~March 31, ~~2016.~~2019.

~~Our first significant~~During 2019, our revenue ~~was~~has mainly been generated through the exclusive negotiation fee recorded in September 9, 2013 and the license and collaboration agreement for our RSV vaccine signed on December 27, 2013. As consideration Mymetics received an irrevocable and non-refundable upfront fee for the license of USD 5 million at the beginning of 2014 and fixed monthly collaboration and R&D fees. This license and collaboration agreement ended in 2016.NIH grant / HIV project. For 2017, we recognized a small amount of revenue related to the Research Agreement with Sanofi Pasteur Biologics, to investigate the immunogenicity of influenza vaccines based on Mymetics’ proprietary virosome technology platform in preclinical settings and anticipate revenue related to the Horizon 2020, ~~project. New~~new significant revenues isare not expected unless and until a ~~second~~ major licensing agreement or other commercial arrangement is entered into with respect to our ~~technology.~~technology or new grant financings are awarded.

As of ~~September 30, 2017,~~March 31, 2020, we had an accumulated deficit of approximately ~~E79 million,~~E90,026, and had net loss of ~~E3,031~~E1,164 in the ~~nine month~~three-month period ending on that date. We expect to continue to incur net losses in the future for research, development and activities related to the future licensing of our technologies, and because of the accrual of interest payable on existing loans.

Net cash used infrom operating activities was ~~E1,659~~E454 for the ~~nine month~~three-month period ended ~~September 30, 2017~~March 31, 2020. During the three-month period ending March 31, 2019 net cash used from operating activities was E9 mainly due to the ~~subcontracting services paid to vendors~~final funding amount received during the three-month period ending March 31, 2019 related to the Maciviva ~~project of E710. During the nine month period ended September 30, 2016 net cash used in operating activities was E1,270.~~project.

Net cash used infrom investing activities was ~~(E34)~~E5 during the ~~nine~~three months ended ~~September 30, 2017, related to~~March 31, 2020 and NIL during the ~~purchase of equipment for our laboratory in Leiden, compared to (E3) for the comparable~~same period in ~~2016.~~2019.

~~Financing~~

Net cash provided from financing activities ~~provided net cash of E1,150 for the nine months ended September 30, 2017, related to promissory notes from our main investors, and~~is NIL for the ~~comparable period~~three months ended ~~September 30, 2016.~~March 31, 2020 and 2019.

Salaries and related payroll costs represent gross salaries for two executives, our CSO of Mymetics BV and seven employees. Under Executive Employment Agreements with our CEO and two CSOs, we pay our executive officers a combined amount of E65 per month.

Our Swiss subsidiary, Mymetics S.A., has, besides the CEO and CSO, two additional employees on its payroll: Director of Finance and Head of Manufacturing and Quality. Mymetics BV has, besides the full time Chief Scientific Officer, ~~three~~two full-time technicians and one part-time assistant.

We intend to continue to incur additional expenditures during the next ~~six~~nine months for additional research and development of our HIV, Influenza vaccines and ~~Chikungunya vaccines,~~immunotherapy projects, which we will try to seek through collaborations with pharmaceutical companies or with not-for-profit organizations. These expenditures will relate to the continued research and testing of ~~its~~these prototype vaccines and are included in the monthly cash outflow described above.

In the past, we have financed our research and development activities primarily through debt and equity financings from various parties ~~while the last three years our financing was generated partially~~and through a license and collaboration ~~agreement~~agreements and grant ~~agreements~~agreements.

We anticipate that our normal operations will require approximately ~~E600 from existing capital resources~~E1,360 of cash in the year ending December 31, ~~2017. Additional~~ ~~promissory notes for a total of E1,150 from our main investors~~ ~~is received in October 2017.~~2020. We will seek to raise ~~additional~~the required capital from equity or debt financings, and grants through donors and potential partnerships with major international pharmaceutical and biotechnology firms. However, there can be no assurance that we will be able to raise additional capital on satisfactory terms, or at all, to finance our operations. In the event that we are not able to obtain such additional capital, we will be required to further restrict or even cease our operations.

Monthly fixed and recurring expenses for "Property leases" of E13 represent the monthly lease and maintenance payments to unaffiliated third parties for our offices, of which E4 is related to our executive office located at Route de la Corniche 4, 1066 Epalinges in Switzerland (100 square meters), and E9 related to Bestewil Holding B.V. and its subsidiary Mymetics B.V operating from a similar biotechnology campus near Leiden in the Netherlands, where they occupy ~~120~~204 square meters.

Included in professional fees are legal fees paid to outside corporate counsel and audit and review fees paid to our independent accountants, and fees paid for investor relations.

Cumulative interest expense of ~~E19,781~~E26,503 has been accrued on all of the Company’s outstanding notes and advances (see detailed table in Note 2 to the financial statements).

Anergis is investigating the possibility to fund a license agreement with Mymetics, but for now nothing is confirmed. In May 2019, the Company started an NIH grant funded project to evaluate the HIV vaccine in a non-human primate study and prepare for clinical trials. Management believes that the Company’s research and development activities will result in valuable intellectual property that can generate significant revenues in the future through licensing since the Company believes that vaccines are one of the fastest growing markets in the pharmaceutical industry.

RECENT FINANCING ACTIVITIES

During the ~~nine~~three month period ending ~~September 30, 2017,~~March 31, 2020, our principal source of funds has been ~~revenues related to the Horizon 2020 Maciviva project and the Research Agreement with Sanofi Pasteur Biologics and additionally~~ promissory notes received in a prior quarter from our two main ~~investors.~~investors and the revenue generated through the NIH grant / HIV project.

We have filed or are in the process of filing several new grant applications with U.S. and European institutions in relation to our virosome based vaccines.

We anticipate using our current funds and those we receive in the future both to meet our working capital needs and for funding the ongoing vaccines pre-clinical research costs for new virosome vaccine.

Management anticipates that our existing capital resources will be sufficient to fund our cash requirements through the next ~~three~~five months. We have cash presently on hand in conjunction with the collection of receivables, based upon our current levels of expenditures and anticipated needs during this period. For ~~2018,~~2020, we will need additional funding through future collaborative arrangements, licensing arrangements, and debt and equity financings under Regulation D and Regulation S under the Securities Act of 1933. We do not know whether additional financing will be available on commercially acceptable terms when needed. These conditions raise substantial doubt about our ability to continue as a going concern.

If management cannot raise funds on acceptable terms when needed, we may not be able to successfully commercialize our technologies, take advantage of future opportunities, or respond to unanticipated requirements. If unable to secure such additional financing when needed, we will have to curtail or suspend all or a portion of our business activities and could be required to cease operations entirely. Further, if new equity securities are issued, our shareholders may experience severe dilution of their ownership percentage.

The extent and timing of our future capital requirements will depend primarily upon the rate of our progress in the research and development of our technologies, our ability to enter into a partnership agreement with a major pharmaceutical company, and the results of our present projects and future clinical trials.

OFF-BALANCE SHEET ARRANGEMENTS

None

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

INTEREST RATE RISK

Fluctuations in interest rates may affect the fair value of financial instruments. An increase in market interest rates may increase interest payments and a decrease in market interest rates may decrease interest payments of such financial instruments. We have no debt obligations which are sensitive to interest rate fluctuations as all our notes payable have fixed interest rates, as specified on the individual loan notes.

ITEM 4.

CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, as appropriate, to allow timely decisions regarding required disclosure. Our management, with the participation and supervision of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and determined that our disclosure controls and procedures were effective.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

No changes of internal control over financial reporting were made in the ~~nine~~three months ended ~~September 30, 2017.~~March 31, 2020.

INHERENT LIMITATIONS ON EFFECTIVENESS OF CONTROLS

Our management, Ronald Kempers, who is ~~now~~ both CEO and CFO, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected.

These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

PART II.

OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

Neither we, nor our wholly owned subsidiaries Mymetics S.A., Bestewil Holding B.V. nor its subsidiary Mymetics B.V. are presently involved in any litigation incident to our business.

ITEM 1A.

RISK FACTORS

Not Applicable

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

None.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

~~EXHIBIT NUMBER~~

~~DESCRIPTION~~

EXHIBIT NUMBER	~~31.1~~ ~~Rule 13a-14(a)/15d-14(a) Certification of Chief~~ ~~31.2~~ ~~Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer~~ 32 ~~Section 1350 Certification of Chief Executive Officer and Chief Financial Officer~~ ~~101.INS~~ ~~Instance Document~~ ~~101.SCH~~ ~~XBRL Taxonomy Extension Schema Document~~ ~~101.CAL~~ ~~XBRL Taxonomy Extension Calculation Linkbase Document~~ ~~101.LAB~~ ~~XBRL Taxonomy Extension Label Linkbase Document~~ ~~101.PRE~~ ~~XBRL Taxonomy Extension Presentation Linkbase Document~~	DESCRIPTION

31.1		Rule 13a-14(a)/15d-14(a) Certification of Chief

31.2		Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer

32		Section 1350 Certification of Chief Executive Officer and Chief Financial Officer

101.INS		Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MYMETICS CORPORATION

Dated: ~~November 13, 2017~~May 15, 2020	By:	/s/ Ronald Kempers
		Chief Executive Officer / Chief Financial Officer

DELAWARE		25-1741849
State or Other jurisdiction of Incorporation or Organization		I.R.S. Employer Identification No.

c/o Mymetics SA Route de la Corniche 4 Epalinges, Switzerland			CH-1066
Address of Principal Executive Offices		Zip Code

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, Par Value $0.01 per share		MYMX		OTCQB venture stage marketplace

			March 31,	December 31,
	September 30,	December 31,	2020	2019
	2017	2016	(unaudited)
ASSETS
Current Assets
Cash	E830	E1,391	E231	E683
Receivables	56	170	321	164
Prepaid expenses	41		69	85
Total current assets	927	1,602	621	932

Property and equipment, net of accumulated depreciation of E363 at September 30, 2017 and E418 at December 31, 2016	73	67
Property and equipment, net of accumulated depreciation of E450 at March 31, 2020 and E445 at December 31, 2019			52
Right-of-Use Asset			205	230
Goodwill	6,671		6,671
	E7,671	E8,340	E7,549	E7,885

LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable	E96	E120	E236	E167
Deferred revenue from grants	733	1,165
Deferred revenue			46	--
Operating lease liability			102
Non-convertible notes payable and related accrued interest to related parties	1,167	--	5,340	5,308
Convertible notes payable and related accrued interest to related parties	47,472	45,834	54,077	53,378
Total liabilities	49,468	47,119
Total current liabilities			59,801	58,955

Long Term Liabilities
Operating lease liability			103	128
Total long-term liabilities			103	128
			59,904	59,083

Shareholders' Equity (Deficit)
Common stock, U.S. $0.01 par value;1,000,000,000 shares authorized; issued 303,757,622 at September 30, 2017 and at December 31, 2016	2,530
Preferred stock, U.S. $0.01 par value; 5,000,000 shares authorized; none issued or Outstanding	--
Commitments and Contingencies (Note 3)			--

Shareholders' Deficit
Common stock, U.S. $0.01 par value; 1,200,000,000 shares authorized; issued and outstanding 303,757,622 at March 31, 2020 and at December 31, 2019			2,530
Preferred stock, U.S. $0.01 par value; 5,000,000 shares authorized; none issued or outstanding			--
Additional paid-in capital	34,423	34,392	34,443
Accumulated deficit	(79,422)	(76,391)	(90,026)	(88,862)
Accumulated other comprehensive income	672	690	698	691
	(41,797)	(38,779)
	E7,671	E8,340
Total shareholders’ deficit			(52,355)	(51,198)
Total liabilities and shareholders’ deficit			E7,549	E7,885

	For The Nine Months Ended September 30,		For The Three Months Ended March 31,
	2017	2016	2020	2019
Cash Flow from Operating Activities
Net loss	E(3,031)	E(2,520)
Net Loss			E(1,164)	E(1,228)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	28	33	5
Stock compensation expense – options	31	63	-	2
Changes in operating assets and liabilities
Receivables	114	163	(157)	537
Accrued interests on notes payable	1,655	1,863
Accrued interests on convertible notes payable			699	697
Accrued interests on non-convertible notes payable			32	24
Accounts payable	(24)	(341)	69	(39)
Deferred revenue from grants	(432)	(528)
Deferred grant			46	--
Other	--	(3)	16	(7)
Net cash used in operating activities	(1,659)	(1,270)	(454)	(9)

Cash Flows from Investing Activities
Purchase of property and equipment	(34)	(3)	(5)	--
Net cash used in investing activities	(34)	(3)	(5)	--

Cash Flows from Financing Activities
Increase in notes payable	1,150	--
Net cash provided by financing activities	1,150	--

Effect of foreign exchange rate on cash	(18)	(4)
Effect on foreign exchange rate on cash			7	5
Net change in cash	(561)	(1,277)	(452)	(4)

Cash, beginning of period	1,391	2,381	683	479
Cash, end of period	E830	E1,104	E231	E475

Supplemental Disclosure of Cash Flow Information:
Cash paid for interest			E--
Cash paid for taxes			8	3

							Fixed						Fixed
						Conversion	Rate					Conversion	Rate
Lender	1st-Issue	Principal		Duration	Interest	Price	EUR/USD	1st-Issue	Principal	Duration	Interest	Price	EUR/USD
Price	Date	Amount		(Note)	Rate	(stated)	Conversion	Date	Amount	(Note)	Rate	(stated)	Conversion

Eardley Holding A.G. (1)	06/23/2006	E	161	(2)	10% pa	$0.10	N/A	06/23/2006	E173	(2)	10% pa	$0.10	N/A
Anglo Irish Bank S.A.(3)	10/21/2007	E	500	(2)	10% pa	$0.50	1.4090	10/21/2007	E500	(2)	10% pa	$0.50	1.4090
Round Enterprises Ltd.	12/10/2007	E	1,500	(2)	10% pa	$0.50	1.4429	12/10/2007	E1,500	(2)	10% pa	$0.50	1.4429
Round Enterprises Ltd.	01/22/2008	E	1,500	(2)	10% pa	$0.50	1.4629	01/22/2008	E1,500	(2)	10% pa	$0.50	1.4629
Round Enterprises Ltd.	04/25/2008	E	2,000	(2)	10% pa	$0.50	1.5889	04/25/2008	E2,000	(2)	10% pa	$0.50	1.5889
Round Enterprises Ltd.	06/30/2008	E	1,500	(2)	10% pa	$0.50	1.5380	06/30/2008	E1,500	(2)	10% pa	$0.50	1.5380
Round Enterprises Ltd.	11/18/2008	E	1,200	(2)	10% pa	$0.50	1.2650	11/18/2008	E1,200	(2)	10% pa	$0.50	1.2650
Round Enterprises Ltd.	02/09/2009	E	1,500	(2)	10% pa	$0.50	1.2940	02/09/2009	E1,500	(2)	10% pa	$0.50	1.2940
Round Enterprises Ltd.	06/15/2009	E	5,500	(2,4)	10% pa	$0.80	1.4045	06/15/2009	E5,500	(2,4)	10% pa	$0.80	1.4045
Eardley Holding A.G.	06/15/2009	E	100	(2,4)	10% pa	$0.80	1.4300	06/15/2009	E100	(2,4)	10% pa	$0.80	1.4300
Von Meyenburg	08/03/2009	E	200	(2)	10% pa	$0.80	1.4400	08/03/2009	E200	(2)	10% pa	$0.80	1.4400
Round Enterprises Ltd.	10/13/2009	E	2,000	(2)	5% pa	$0.25	1.4854	10/13/2009	E2,000	(2)	5% pa	$0.25	1.4854
Round Enterprises Ltd.	12/18/2009	E	2,200	(2)	5% pa	$0.25	1.4338	12/18/2009	E2,200	(2)	5% pa	$0.25	1.4338
Round Enterprises Ltd.	08/04/2011	E	1,016	(5,6)	10% pa	$0.034	N/A	08/04/2011	E1,091	(5,6)	10% pa	$0.034	N/A
Eardley Holding A.G.	08/04/2011	E	254	(5,6)	10% pa	$0.034	N/A	08/04/2011	E273	(5,6)	10% pa	$0.034	N/A
Round Enterprises Ltd.	11/08/2011	E	400	(6)	10% pa	$0.034	1.3787	11/08/2011	E400	(6)	10% pa	$0.034	1.3787
Eardley Holding A.G.	11/08/2011	E	100	(6)	10% pa	$0.034	1.3787	11/08/2011	E100	(6)	10% pa	$0.034	1.3787
Round Enterprises Ltd.	02/10/2012	E	1,000	(6)	10% pa	$0.034	1.3260	02/10/2012	E1,000	(6)	10% pa	$0.034	1.3260
Eardley Holding A.G.	02/14/2012	E	200	(6)	10% pa	$0.034	1.3260	02/14/2012	E200	(6)	10% pa	$0.034	1.3260
Round Enterprises Ltd.	04/19/2012	E	322	(6)	10% pa	$0.034	1.3100	04/19/2012	E322	(6)	10% pa	$0.034	1.3100
Eardley Holding A.G.	04/19/2012	E	80	(6)	10% pa	$0.034	1.3100	04/19/2012	E80	(6)	10% pa	$0.034	1.3100
Round Enterprises Ltd.	05/04/2012	E	480	(6)	10% pa	$0.034	1.3152	05/04/2012	E480	(6)	10% pa	$0.034	1.3152
Eardley Holding A.G.	05/04/2012	E	120	(6)	10% pa	$0.034	1.3152	05/04/2012	E120	(6)	10% pa	$0.034	1.3152
Round Enterprises Ltd.	09/03/2012	E	200	(6)	10% pa	$0.034	1.2576	09/03/2012	E200	(6)	10% pa	$0.034	1.2576
Eardley Holding A.G.	09/03/2012	E	50	(6)	10% pa	$0.034	1.2576	09/03/2012	E50	(6)	10% pa	$0.034	1.2576
Round Enterprises Ltd.	11/14/2012	E	500	(6)	10% pa	$0.034	1.2718	11/14/2012	E500	(6)	10% pa	$0.034	1.2718
Eardley Holding A.G.	12/06/2012	E	125	(6)	10% pa	$0.034	1.3070	12/06/2012	E125	(6)	10% pa	$0.034	1.3070
Round Enterprises Ltd.	01/16/2013	E	240	(6)	10% pa	$0.034	1.3318	01/16/2013	E240	(6)	10% pa	$0.034	1.3318
Eardley Holding A.G.	01/16/2013	E	60	(6)	10% pa	$0.034	1.3318	01/16/2013	E60	(6)	10% pa	$0.034	1.3318
Round Enterprises Ltd.	03/25/2013	E	400	(6)	10% pa	$0.037	1.2915	03/25/2013	E400	(6)	10% pa	$0.037	1.2915
Eardley Holding A.G.	04/14/2013	E	150	(6)	10% pa	$0.034	1.3056	04/14/2013	E150	(6)	10% pa	$0.034	1.3056
Round Enterprises Ltd.	04/14/2013	E	600	(6)	10% pa	$0.034	1.3056	04/14/2013	E600	(6)	10% pa	$0.034	1.3056
Eardley Holding A.G.	05/15/2013	E	170	(6)	10% pa	$0.037	1.2938	05/15/2013	E170	(6)	10% pa	$0.037	1.2938
Round Enterprises Ltd.	05/15/2013	E	680	(6)	10% pa	$0.037	1.2938	05/15/2013	E680	(6)	10% pa	$0.037	1.2938
Eardley Holding A.G.	06/24/2013	E	60	(6)	10% pa	$0.025	1.3340	06/24/2013	E60	(6)	10% pa	$0.025	1.3340
Round Enterprises Ltd.	06/24/2013	E	240	(6)	10% pa	$0.025	1.3340	06/24/2013	E240	(6)	10% pa	$0.025	1.3340
Eardley Holding A.G.	08/05/2013	E	80	(6)	10% pa	$0.018	1.3283	08/05/2013	E80	(6)	10% pa	$0.018	1.3283
Round Enterprises Ltd.	08/05/2013	E	320	(6)	10% pa	$0.018	1.3283	08/05/2013	E320	(6)	10% pa	$0.018	1.3283
Eardley Holding A.G.	03/01/2017	E	230	(7)	2.5% pa	N/A		03/01/2017	E230	(2)	2.5% pa	N/A
Round Enterprises Ltd.	03/01/2017	E	920	(7)	2.5% pa	N/A		03/01/2017	E920	(2)	2.5% pa	N/A
Eardley Holding A.G.								10/18/2017	E230	(2)	2.5% pa	N/A
Round Enterprises Ltd.								10/18/2017	E920	(2)	2.5% pa	N/A
Eardley Holding A.G.								06/01/2018	E160	(7)	2.5% pa	N/A
Round Enterprises Ltd.								06/01/2018	E640	(7)	2.5% pa	N/A
Eardley Holding A.G.								11/10/2018	E160	(7)	2.5% pa	N/A
Round Enterprises Ltd.								11/10/2018	E640	(7)	2.5% pa	N/A
Eardley Holding A.G.								06/15/2019	E120	(8)	2.5% pa	N/A
Round Enterprises Ltd.								06/15/2019	E480	(8)	2.5% pa	N/A
Eardley Holding A.G.								12/20/2019	E120	(9)	2.5% pa	N/A
Round Enterprises Ltd.								12/20/2019	E480	(9)	2.5% pa	N/A
Total Short Term Principal Amounts		E	28,858						E32,914
Accrued Interest		E	19,781						E26,503

TOTAL LOANS AND NOTES		E	48,639						E59,417